Michelson Medical Research Foundation’s State Street SPDR S&P Regional Banking ETF KRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.75M Hold
63,510
4.39% 9
2026
Q1
$4.14M Hold
63,510
4.2% 9
2025
Q4
$4.12M Hold
63,510
4.13% 9
2025
Q3
$4.02M Hold
63,510
3.5% 11
2025
Q2
$3.77M Sell
63,510
-13,590
-18% -$757K 3.62% 11
2025
Q1
$4.38M Hold
77,100
3.67% 10
2024
Q4
$4.65M Sell
77,100
-37,600
-33% -$2.33M 3.9% 10
2024
Q3
$6.49M Hold
114,700
4.58% 8
2024
Q2
$5.63M Hold
114,700
4.84% 8
2024
Q1
$5.77M Hold
114,700
3.5% 11
2023
Q4
$6.01M Hold
114,700
3.97% 10
2023
Q3
$4.79M Buy
+114,700
New +$5.11M 3.23% 11

Other funds holding KRE

Michelson Medical Research Foundation's KRE Position: Q2 2026 in Review

Michelson Medical Research Foundation held its State Street SPDR S&P Regional Banking ETF (KRE) position steady in Q2 2026 at 63,510 shares worth $4.75M. The position accounts for 4.39% of the portfolio, ranked #9.

Michelson Medical Research Foundation first reported a position in KRE in Q3 2023 and has held it in 12 quarters since. The position peaked at $6.49M in Q3 2024. 544 funds tracked by Wall St. Rank hold KRE as of Q2 2026.

  • Michelson Medical Research Foundation held 63,510 shares of State Street SPDR S&P Regional Banking ETF worth $4.75M as of Q2 2026.
  • Michelson Medical Research Foundation left its State Street SPDR S&P Regional Banking ETF share count unchanged in Q2 2026.
  • State Street SPDR S&P Regional Banking ETF made up 4.39% of Michelson Medical Research Foundation's portfolio in Q2 2026, its #9 holding.
  • Michelson Medical Research Foundation first reported a position in State Street SPDR S&P Regional Banking ETF in Q3 2023 and has held it in 12 quarters since.
  • Michelson Medical Research Foundation's State Street SPDR S&P Regional Banking ETF position peaked at $6.49M in Q3 2024.
  • 544 funds tracked by Wall St. Rank held State Street SPDR S&P Regional Banking ETF as of Q2 2026.

Based on Michelson Medical Research Foundation's 13F filing for Q2 2026, filed 14 Aug 2026.